RE: expecting a fall... but how low?15 Apr 2019 14:29
The alternative would be a situation where they could not determine the reason for the drug not performing well In Vivo and it would be game over.
So IMO, the RNS is excellent news. They acknowledge they cocked up the comms with UQ in describing the test environment and are now making amends to resolve this.
No mention of a share placing either as it sounds like they are prioritising Nuvec over other commitments (whatever they are).